This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Andrew A. Skolnick

JAMA. 1998;280:124.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE SECURITIES and Exchange Commission (SEC) has accused another biomedical researcher of illegally profiting on the stock market by using insider information about biomedical products.

On June 17, the SEC announced that Changnian Liu, PhD, of Omaha, Neb, has agreed to a permanent injunction from future violations of the antifraud provisions of the federal securities laws. In a consent agreement neither admitting nor denying allegations, the former researcher for the biotechnology company Immunogen Inc, of Norwood, Mass, has also agreed to give up $41700 of illegal trading profits plus $6633 in prejudgment interest and to pay a civil monetary penalty of $41700, the SEC said.

The SEC complaint alleges that Liu illegally profited from insider information by buying stock in his company in advance of the publication of a study that showed the firm's new pharmaceutical compound completely eliminated human colon tumors grown in mice. Liu was . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?